The only way to manage neurodegeneration in MS is to prevent it with effective anti-inflammatory therapy: No

Abstract

Get full access to this article

View all access options for this article.

References

Trapp

Peterson

Ransohoff

. Axonal transection in the lesions of multiple sclerosis. N Engl J Med 1998; 338: 278–285.

Confavreux

Vukusic

Moreau

. Relapses and progression of disability in multiple sclerosis. N Engl J Med 2000; 343: 1430–1438.

Confavreux

Vukusic

Adeleine

. Early clinical predictors and progression of irreversible disability in multiple sclerosis: An amnesic process. Brain 2003; 126 (Pt 4): 770–782.

Coles

Wing

Molyneux

. Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis. Ann Neurol 1999; 46: 296–304.

Coles

Compston

Selmaj

. Alemtuzumab vs. interferon beta-1a in early multiple sclerosis. N Engl J Med 2008; 359: 1786–1801.

Hawker

O’Connor

Freedman

. Rituximab in patients with primary progressive multiple sclerosis: Results of a randomized double-blind placebo-controlled multicenter trial. Ann Neurol 2009; 66: 460–471.

Bieber

Kerr

Rodriguez

. Efficient central nervous system remyelination requires T cells. Ann Neurol 2003; 53: 680–684.

Kapoor

Furby

Hayton

. Lamotrigine for neuroprotection in secondary progressive multiple sclerosis: A randomised, double-blind, placebo-controlled, parallel-group trial. Lancet Neurol 2010; 9: 681–688.

Stadelmann

. Multiple sclerosis as a neurodegenerative disease: Pathology, mechanisms and therapeutic implications. Curr Opin Neurol 2011; 24: 224–229.